Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.
about
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetesGLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependenceIncretins and the intensivist: what are they and what does an intensivist need to know about them?The entero-insular axis: implications for human metabolism.Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiencyModels of glucagon secretion, their application to the analysis of the defects in glucagon counterregulation and potential extension to approximate glucagon action.Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine.Effects of insulin and octreotide on memory and growth hormone in Alzheimer's diseaseQuantifying the contribution of the liver to glucose homeostasis: a detailed kinetic model of human hepatic glucose metabolismEmerging role of insulin with incretin therapies for management of type 2 diabetes.GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic miceEffects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humansMetabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetesThe incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management.Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemiaInvestigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.Biologic actions and therapeutic potential of the proglucagon-derived peptides.Management of Type 2 diabetes: the role of incretin mimetics.Rationale and design of Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-group study.Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeksGlucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brainAutonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats.Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventionsEvolution of exenatide as a diabetes therapeutic.Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity.Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver.Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretinsEfficient (18)F-Labeling of Synthetic Exendin-4 Analogues for Imaging Beta CellsIncretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge.The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.Exogenous glucagon-like peptide-1 for hyperglycemia in critically ill patients.GLP-1 based therapies: differential effects on fasting and postprandial glucose.Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings.Exenatide extended-release: a review of its use in type 2 diabetes mellitus.Differentiation of stem cells into insulin-producing cells: current status and challenges.Glucagon: the renewal of an old hormone in the pathophysiology of diabetes.The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists.
P2860
Q26827955-0C47AF89-57B5-4A49-ABF8-66ABBB825CB7Q26858990-ABC2D950-B091-48E9-A79B-B934FCDF6B37Q26995464-EED652FC-DDB2-4A7E-AB4D-53BD8D7F4003Q30365939-7A5CD6F1-8764-4985-BBC7-34EA02B77357Q30424699-91A9CE8F-77E9-44CB-9FE6-BF5CEA0E2F53Q30429992-8A01D5C7-8257-4DE0-A1F6-123DD6383C14Q30438126-0B6B0C9F-2F6B-47DF-AF06-26AD209243B9Q33742199-15A01928-49EA-4045-87D7-F9BC8B92F700Q34325481-FFD02A21-7937-47C7-9A62-7E350F585033Q35214425-EC3C1A96-49A0-40FE-BE05-9AE3A406B46BQ35226164-45FA2BB1-0E7E-48E5-8C00-831B2B849DDEQ35673081-9D75B788-D203-4C3D-BB27-186B193C9C61Q35913076-27B7321F-9C2B-4BCC-BCF8-B2D50474166BQ36012896-06CA8160-6C82-461C-A1CC-21AFBC178F8CQ36187070-B07CD335-D0B7-4A7F-9F61-42FD9FE3C28CQ36407215-1D4A8D9F-B4CA-4123-A178-66B721DB5724Q36459067-ABD32A74-09D6-470B-ACAB-48BB72BEE536Q36543063-FD194B58-4EF4-4A81-812D-A09C6532A294Q36575421-5EF942C1-BD71-4F89-B8EE-8DDE69E27EFFQ36613938-3330A033-63E7-4160-B161-48FEA08BBF2DQ36625415-3003D561-0B7F-49B8-ADA0-9B4E626DBB5DQ36670931-B4BBDABD-495A-4EF3-9D66-0678AB459E7CQ36718544-F49D7B97-399F-4DA5-8309-062762AB20B3Q36735857-2C3BDC45-DB1D-4C5D-849B-7AC9635716DDQ36740436-2036C5A9-5EE6-4510-8463-5D8387A8809FQ36877205-4F795169-47F8-44D3-AF66-CC8A7FC11244Q36942260-25477BCF-BEE6-492A-B755-1E76099B5BA6Q37066877-C052B222-303F-42F3-9851-3382211A8525Q37091579-74030FE1-1E3B-4711-9E50-B45C13A942BBQ37134464-51F02A4F-5F1E-45A9-917A-175E77A99DC0Q37780914-A758BF75-45FB-4C72-B05D-D33ED9A87321Q37864256-78445A93-A587-45B8-82BC-88F7DC0E3462Q37867193-C901EE1C-DD2B-455B-A3F1-9DB5F5E4B7A2Q37971830-F24E1045-7C50-4142-BBB3-75938BE570BEQ37974712-356B7EC4-9753-4315-8ABE-6B2C6EC49670Q38014516-D30AF759-2518-4BED-BF6C-03CC265D12E2Q38032321-16A8C4A5-5D09-4C52-9A16-945F5E82C54AQ38071243-C80C3244-81B4-461B-8B81-283CDE5DB10EQ38072773-09D23DAB-041D-4688-909B-B12B8C13023EQ38088195-735FF4A7-DF47-4819-9B24-6A5F954876F4
P2860
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Effect of intravenous infusion ...... egulation during hypoglycemia.
@en
Effect of intravenous infusion of exenatide
@nl
type
label
Effect of intravenous infusion ...... egulation during hypoglycemia.
@en
Effect of intravenous infusion of exenatide
@nl
prefLabel
Effect of intravenous infusion ...... egulation during hypoglycemia.
@en
Effect of intravenous infusion of exenatide
@nl
P2093
P1433
P1476
Effect of intravenous infusion ...... egulation during hypoglycemia.
@en
P2093
Birgitte Brock
Christian B Djurhuus
Claus B Juhl
Dennis Kim
Jaime Grubert
Kristin Taylor
Kristine B Degn
Mark Fineman
Ole Schmitz
P304
P356
10.2337/DIABETES.53.9.2397
P407
P577
2004-09-01T00:00:00Z